In a groundbreaking development, Moderna has received FDA approval for its cutting-edge COVID-19 vaccine, paving the way for its release in the upcoming 2025–2026 respiratory virus season. This milestone comes in the wake of the FDA’s introduction of a new approval framework for COVID-19 vaccines, signaling a new era in vaccine regulation. The announcement also follows recent statements by HHS Secretary Robert F. Kennedy Jr. regarding changes to CDC guidelines on COVID-19 vaccination for healthy children and pregnant women, providing a complex backdrop to the evolving landscape of public health policy. With the approval of this mRNA therapeutic, Moderna continues to lead the way in innovative biotech solutions, offering hope for a safer and healthier future for all.
Read more about this — here
